AZD5492
Sponsors
AstraZeneca AB, AstraZeneca
Conditions
B-Cell MalignanciesB-cell MalignanciesIdiopathic Inflammatory MyopathiesRheumatoid ArthritisSystemic Lupus Erythematosus
Phase 1
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingNCT06542250
Start: 2024-09-18End: 2029-12-18Target: 174Updated: 2026-08-07
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)
RecruitingCTIS2024-511099-34-00
Start: 2024-12-12Target: 66Updated: 2026-01-19
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
RecruitingNCT06916806
Start: 2025-05-01End: 2027-09-15Target: 72Updated: 2026-09-15